YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM L... (ence reached statistical significance (p...)

HOME >> BIOLOGY >> TECHNOLOGY

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM LUNG CANCER

Date:1/5/2009

ence reached statistical significance (p= 0.0039, Log Rank test).

About nimotuzumab

Nimotuzumab is currently being advanced in several randomized Phase II and III trials in Japan, South East Asia, Europe and elsewhere and is undergoing a YM-sponsored confirmatory trial in pediatric glioma in Canada and the US. The National Cancer Centre of Singapore (NCCS) recently announced that it has selected nimotuzumab for evaluation in the adjuvant setting in a multinational Phase III trial of more than 700 patients with cancers of the head and neck. The NCCS stated that it selected nimotuzumab because of its reported preferential safety profile compared with other EGFR-targeting cancer drugs.

Nimotuzumab is being developed to compete as best-in-class therapy against the currently marketed EGFR-targeting drugs. This drug has displayed efficacy in numerous tumour types (published and presented at major conferences including ASCO), having completed more than 27 clinical trials and having demonstrated anti-cancer activity that rivals the other EGFR-targeting antibody drugs.

In none of the clinical trials of nimotuzumab to date, to YM's knowledge, have any of the patients developed Grade III/IV acneiform rash, also a severe and dose-limiting side-effect observed in all of the other antibodies and with small molecules targeting the EGF tyrosine kinase signaling pathway. Unrelated to the rash, Grade III/IV radiation dermatitis is a severe toxicity reported in almost half the patients treated with another EGFR-targeting antibody drug in combination with radiation in head and neck cancer while absent in nimotuzumab/radiation treated patients. Reports of any severe incidents of the other side-effects that are typical of EGFR-targeting molecules have been rare. These severe side-effects can result in treatment interruptions, one of the leading causes of treatment failure and, unlike cetuximab, nimotuzumab patients do not have to be pre-m
'/>"/>

SOURCE YM BioSciences Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7
Related biology technology :

1. YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 26
2. Selection of Development Candidate Triggers $0.5 Million Milestone Payment to Ardea Biosciences, Inc.
3. ImmuneRegen BioSciences Files 8-K that Highlights Enclosed Shareholder Letter Discussing Recent Achievements and Outlook
4. ONCOSCIENCE AG, THE EUROPEAN PARTNER OF YM BIOSCIENCES, ANNOUNCES COMPLETION OF PATIENT ENROLLMENT IN PHASE III BRAIN CANCER TRIAL OF NIMOTUZUMAB
5. Pressure BioSciences, Inc. Reports Second Quarter 2007 Financial Results and Provides Business Update
6. YM BIOSCIENCES, EUROPEAN PARTNER, ONCOSCIENCE AG, ANNOUNCES INITIATION OF ADVANCED NIMOTUZUMAB TRIALS IN ADULT GLIOMA AND PANCREATIC CANCER
7. Monogram Biosciences to Present at the Thomas Weisel Partners Healthcare Conference 2007
8. Magellan Biosciences Names Steven E. Diamond, PhD, Chief Scientific Officer
9. Pressure BioSciences, Inc. Issued First Patent in Canada
10. Neurocrine Biosciences to Present at the BioCentury: Newsmakers in the Biotech Industry Conference
11. YM BioSciences USA cleared by US FDA to initiate Phase II clinical trial of nimotuzumab in children with inoperable, recurrent brain cancer

Post Your Comments:

(Date:12/16/2009)... 16 Decision Resources, one of the ... and healthcare issues, finds that, according to responses ... Abbott,s briakinumab (both interleukin inhibitors) will capture 22 ... the drug market for moderate to severe psoriasis. ... uptake, capturing nearly three times as much patient ...

(Date:12/16/2009)... CHO cell culture supplement? InVitria has what scientists have been ... supplement that improves the growth and productivity of CHO cells. ... is an animal free, well defined and consistent recombinant CHO ... ... (PRWEB) December 16, 2009 -- Scientists working with CHO cells ...

(Date:12/15/2009)... SAN MARINO, Calif., Dec. 15 Epeius ... of targeted genetic medicine, gained international validation of ... Rexin-G , when scientists around the world ... be a major locus of cancer pathogenesis and ... anti-cancer therapies. Recently, scientists at the NIH National ...

(Date:12/15/2009)... Reportlinker.com announces that a new ... catalogue: ,, The Future of ... 2015, Pipeline Analysis and Reimbursement ... ,, Summary ,, The author ... of Orphan Diseases Therapeutics - Market Forecasts ...

[0] In 2012, Stelara and Briakinumab Will Capture 22 Percent of the Biologics Share in the Moderate to Severe Psoriasis Drug Market [0] Online Video of InVitria's Zap-CHO Helps Scientists Maximize CHO Cell Culture Performance [0] Scientists Rediscover Gene Target for Cancer Therapy [0] Reportlinker Adds The Future of Orphan Diseases Therapeutics - Market Forecasts to 2015, Pipeline Analysis and Reimbursement

... JobLoft.com, a leading online job,board that lists ... on,geographic proximity, announced today the expansion of ... acquisition of RegionalHelpWanted.com by,its parent company, onTargetjobs. ... 350 geographically focused,Internet job boards, JobLoft.com now ...

... Efficacy Will Drive Prescription Rates, According ... to a New Report from Decision ... one of the,world,s leading research and advisory firms focusing ... in early 2009,Centocor/Janssen-Cilag,s ustekinumab will become the clinical gold ...

... - Data on ARIUS, novel CD9 therapeutic antibody to be ... Special Conference on ... ARIUS Research Inc., (TSX:,ARI), a biotechnology company discovering and developing ... on the,preclinical activity of its anti-CD9 cancer stem cell antibody ...

Other Biology Technology:JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition 2 Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 2 ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 2 ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 3 ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells 4

JobLoft.com Strengthens Local Market Candidate Reach Through RegionalHelpWanted.com Acquisition Centocor/Janssen-Cilag's Ustekinumab Will Become the Gold Standard for Psoriasis By 2011 ARIUS presents new findings showing therapeutic antibody inhibits human leukemic cancer stem cells

(Date:12/16/2009)... European Union (EU) member states ... which are increasingly subjected to unauthorised immigration ... advanced technology security and IT-based systems will ... http://www.newscom.com/cgi-bin/prnh/20081117/FSLOGO ) ,, New analysis from ... Border Security Market Assessment - European Union ...

(Date:12/15/2009)... soon as babies are born, they are susceptible to ... up to a month, their immune systems aren,t adequately ... minor, they can lead to serious problems if left ... Missouri researchers have pinpointed a group of depleted white ... , "We,re trying to improve the immune system of ...

(Date:12/15/2009)... signed an agreement with the British Society for Research ... the journal Biogerontology for an initial period ... member of the Biogerontology editorial board and ... Springer will sponsor the society and provide society members ... www.springerlink.com . , Biogerontology offers a ...

Breaking Biology News(10 mins):Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 2 Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan 3 Researchers work on vaccine to improve immune system in newborns 2 Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 1 Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 2 Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 3 Elbit Imaging Ltd Announces Swiss Team Uses InSightecs ExAblate 28R 29 4000 Brain System to Treat Patients With Functional Brain Disorders 4721 4 Simulating medical situations helps students learn retain basic science concepts 51568 1 Simulating medical situations helps students learn retain basic science concepts 51568 2 July August 2009 Annals of Family Medicine tip sheet 51565 1 July August 2009 Annals of Family Medicine tip sheet 51565 2 July August 2009 Annals of Family Medicine tip sheet 51565 3 July August 2009 Annals of Family Medicine tip sheet 51565 4 July August 2009 Annals of Family Medicine tip sheet 51565 5 July August 2009 Annals of Family Medicine tip sheet 51565 6 July August 2009 Annals of Family Medicine tip sheet 51565 7

[0] Increased Spending on the EU's External Borders to Drive the Border Security Market, Says Frost & Sullivan [0] Researchers work on vaccine to improve immune system in newborns [0] Springer signs agreement with British Society of Research on Ageing

... thrives in salty conditions may now be better understood ... tolerance has been found in the arabidopsis plant by ... team. , Complex-N-glycan, a carbohydrate linked to a ... no helpful function for plant growth and to cause ...

... new, high-resolution, interactive map of U.S. carbon dioxide emissions ... all where we thought. , "For example, we,ve been ... and it,s looking like the southeastern U.S. is a ... Kevin Gurney, an assistant professor of earth and atmospheric ...

... of the sexes may begin in the womb, researchers from ... a male twin can compromise the health of his ... new study recently published in the journal Pediatrics, the researchers ... found in pre-term twins. When born premature, girls who share ...

Other Biology News:Salt-tolerant gene found in simple plant nothing to sneeze at 2 'Revolutionary' CO2 maps zoom in on greenhouse gas sources 2 'Revolutionary' CO2 maps zoom in on greenhouse gas sources 3 'Revolutionary' CO2 maps zoom in on greenhouse gas sources 4 'Revolutionary' CO2 maps zoom in on greenhouse gas sources 5 War between the sexes begins before twins' birth, TAU researchers say 2

Salt-tolerant gene found in simple plant nothing to sneeze at 'Revolutionary' CO2 maps zoom in on greenhouse gas sources War between the sexes begins before twins' birth, TAU researchers say

... demand is causing shortages in your laboratory ... can cause unwanted distractions, problems and delays. ... for your hard work and endeavour! Bring ... it up,and market it internationally. We work ...

... I from vaccinia virus is a type ... and negative superhelical turns (also called right- ... The product of the reaction is a ... or negative superhelical turns. DNA Topoisomerase I ...

...

... is a unique agarose-digesting enzyme developed by ... intact DNA or RNA from agarose gels. ... melting point (LMP) agarose melted at 6575C ... the reaction temperature before hydrolysis. Simply place ...

Biology Products:

Mycoplasma Testing from AbD Serotec Vaccinia DNA Topoisomerase I from EPICENTRE Biotechnologies Xho I from Roche Applied Science AgarACE Enzyme from Promega

YM BIOSCIENCES RECEIVES CLEARANCE TO INITIATE RANDOMIZED DOUBLE-BLIND CLINICAL TRIALS OF NIMOTUZUMAB IN LUNG CANCER AND BRAIN METASTASES FROM L...(ence reached statistical significance (p...)